Literature DB >> 31432187

Yeast extract inhibits the proliferation of renal cell carcinoma cells via regulation of iron metabolism.

Daeun Moon1, Jinu Kim1, Sang-Pil Yoon1.   

Abstract

The microbiome has recently attracted research interest in a variety of subjects, including cancer. In the present study, it was determined that reinforced clostridium media (RCM) for microbiome culture, exerts antitumor effects on renal cell carcinoma cells when compared to the microbiome 'X'. The antitumor effects of RCM were investigated for all ingredients of RCM, and the results revealed that yeast extract could be a candidate for the ingredient driving this phenomenon. Further experiments including MTT assay, cell counting, cell death analysis, cell cycle analysis and western blotting were conducted with yeast extract on renal cell carcinoma cells (Caki‑1 and Caki‑2) and normal human proximal tubular cells (HK‑2). As a result, yeast extract exhibited dose‑dependent antitumor effects on Caki‑1 and Caki‑2, but only slight effects on HK‑2. In addition, yeast extract only exhibited slight effects on necrosis, autophagy, or apoptosis of Caki‑1 and Caki‑2. Yeast extract produced cell cycle arrest with an increased G0/G1 fraction and a decreased S fraction, and this was considered to be related to the decreased cyclin D1. Although yeast extract treatment increased anti‑oxidant activities, the antitumor effects of yeast extract were also related to iron metabolism, based on the decreased transferrin receptor and increased ferritin. In addition, decreased GPX4 may be related to iron‑dependent cell death, particularly in Caki‑2. These results revealed that yeast extract may inhibit proliferation of renal cell carcinoma cells by regulating iron metabolism. Since an increased iron requirement is a classic phenomenon of cancer cells, yeast extract may be a candidate for adjuvant treatment of renal cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31432187     DOI: 10.3892/mmr.2019.10593

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  5 in total

1.  A novel ferroptosis-related 12-gene signature predicts clinical prognosis and reveals immune relevancy in clear cell renal cell carcinoma.

Authors:  Yingkai Hong; Mingen Lin; Dehua Ou; Zhuangkai Huang; Peilin Shen
Journal:  BMC Cancer       Date:  2021-07-19       Impact factor: 4.430

2.  The Landscape of Iron Metabolism-Related and Methylated Genes in the Prognosis Prediction of Clear Cell Renal Cell Carcinoma.

Authors:  Yanhua Mou; Yao Zhang; Jinchun Wu; Busheng Hu; Chunfang Zhang; Chaojun Duan; Bin Li
Journal:  Front Oncol       Date:  2020-05-22       Impact factor: 6.244

3.  SNU-333 Cells as an Appropriate Cell Line for the Orthotopic Renal Cell Carcinoma Model.

Authors:  Inyoub Chang; Takbum Ohn; Daeun Moon; Young Hee Maeng; Bo Gun Jang; Sang-Pil Yoon
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

4.  Establishing a prognostic model of ferroptosis- and immune-related signatures in kidney cancer: A study based on TCGA and ICGC databases.

Authors:  Zhijun Han; Hao Wang; Jing Long; Yanning Qiu; Xiao-Liang Xing
Journal:  Front Oncol       Date:  2022-08-26       Impact factor: 5.738

5.  Identification of Five Ferroptosis-Related LncRNAs as Novel Prognosis and Diagnosis Signatures for Renal Cancer.

Authors:  Xiangjun Shu; Zaiqi Zhang; Zhi-Yong Yao; Xiao-Liang Xing
Journal:  Front Mol Biosci       Date:  2022-01-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.